

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparin Pharmaceutical Group Co., Ltd. (the **Company**, together with its subsidiaries, the **Group**), in accordance with the Inside Information Provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The Board of Directors (the **Directors**) of the Company (the **Board**) is hereby notified of the Shareholders of the Company (the **Shareholders**) and the Italian Techdow Pharmaceutical S.R.L., a wholly owned subsidiary of the Company (the **Techdow Italy**), is involved in a business deal with a pharmaceutical company (the **Incident**). The Company has been informed of the incident by the Italian company. The Italian company has filed a case with the Italian courts in the name of the Italian company. The Board of Directors of the Company is hereby notified of the incident and is hereby notified of the incident.

The Board of Directors of the Company has hereby notified the Shareholders of the Company of the incident and the Board of Directors of the Company has hereby notified the Shareholders of the Company of the incident. The Board of Directors of the Company has hereby notified the Shareholders of the Company of the incident. The Board of Directors of the Company has hereby notified the Shareholders of the Company of the incident.

The independent director of the Company, Mr. Li Li, has received the TechLink IAB's handling of the ICD. After the investigation of the ICD, Mr. Li Li, the independent director, has concluded that the Company's financial statements for the year ended 31 December 2023 (**FY2023**).

The Company's independent director of the ICD, Mr. Li Li, has concluded that the Company's financial statements for the year ended 31 December 2023 are fair and reasonable.

The Board of Directors has the full and sole power of the Company, and the Board of Directors is the legal representative of the Company.

The Company will take full and complete responsibility for the Shareholders and independent directors of the Company, and the Company will be responsible for the Company's financial statements for the year ended 31 December 2023 (**Annual Results**), which is expected to be published in March 2024, and the Company will be responsible for the Company's financial statements for the year ended 31 December 2023.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 15, 2024

As a reminder of his announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Y and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Li Chan, Mr. Hang Peng and Mr. Yi Ming.